Health & Medical · Week of Nov 2, 2026
Earnings, a dialysis asset sale and heart trial data lead the week
Q3 results from Waters and Syra Health, a dialysis asset sale, a flood-closed rehab hospital, and new data on heart procedures and genome sequencing.
Earnings and portfolio reshaping led the week. Waters Corporation raised its full-year 2026 guidance after third-quarter revenue of $1.767 billion and announced the acquisition of MOBILion Systems, while Syra Health reported its third consecutive profitable quarter. Vantive agreed to sell most of its hemodialysis business to Rockwell Medical, saying it will focus on home dialysis and critical care. Encompass Health reaffirmed its guidance even as it closed a 90-bed Florida rehabilitation hospital after flooding.
On the research side, NYU Langone Health researchers reported that routine invasive procedures for stable heart disease showed no long-term survival advantage over drug therapy, and Illumina was selected to sequence genomes for about 450,000 people in Singapore's SG-INSIGHT study. Company-commissioned data also appeared from Elanco, which surveyed U.S. pet owners on spending, and Nootropics Depot, which published lab measurements of competing supplements.
Waters Corporation
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Waters reported third quarter 2026 revenue of $1.767 billion, including $896 million from the acquired Biosciences and Diagnostic Solutions businesses, and adjusted EPS of $4.10. It raised full-year guidance to total reported revenue of $6.479 billion to $6.497 billion and announced it has acquired MOBILion Systems, a developer of SLIM high-resolution ion mobility separation technology.
Syra Health
Syra Health Delivers Third Consecutive Profitable Quarter: Record Revenue of $2.6 Million, Up 52%, and 46.3% Gross Margin
Syra Health reported Q3 2026 revenue of $2,557,295, up 52%, with net income of $344,610 and a gross margin of 46.3%, and said this was its third consecutive profitable quarter. The company says it is recruiting Accountable Care Organizations to use Syrenity with partner HealthSync, following CMS approval of Syrenity for the ACCESS Model.
Encompass Health Corp.
Encompass Health announces indefinite closure of Sea Pines Rehabilitation Hospital due to flood damage
Encompass Health said the 90-bed Sea Pines Rehabilitation Hospital in Melbourne, Florida, is closed indefinitely after flooding on Nov. 1-2, 2026. The company says all patients were safely evacuated. It reaffirmed its Full-Year 2026 Guidance and noted Sea Pines contributed approximately $14 million to Adjusted EBITDA in the first nine months of 2026.
Elanco Animal Health
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Elanco released an online survey of 2,018 U.S. adults, including 1,495 dog and cat owners, in which 7 percent said they would cut pet health spending under economic pressure. The survey, commissioned by the company, found 38% of pet owners have shifted medication purchasing outside the clinic in the past year or two.
VANTIVE US HEALTHCARE LLC
Vantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell Medical
Vantive agreed to divest the majority of its hemodialysis assets, including concentrates, HD monitors, water treatment systems and its Medolla, Italy manufacturing facility, to Rockwell Medical, with closing expected in mid-2027. The dialyzer portfolio, including Theranova, is excluded, and Vantive says the deal sharpens its focus on home dialysis and critical care.
Illumina, Inc.
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Illumina was selected through an international competitive tender to provide whole-genome sequencing for SG-INSIGHT, a cohort under Phase III of Singapore's National Precision Medicine programme expected to include approximately 450,000 individuals. The study aims to link genomic information with real-world health data and support genetic screening in Singapore's public healthcare system.
NYU Grossman School of Medicine and NYU Langone Health
Routine Invasive Procedures for Stable Heart Disease Offer No Long-Term Survival Advantage Over Drug Therapy
NYU Langone Health researchers said ISCHEMIA-EXTEND, which followed more than 5,000 patients with stable coronary artery disease, found a 26 percent chance of death with an invasive approach versus 27 percent with a conservative approach after nearly a decade. The results were presented November 7, 2026, at the American Heart Association's Scientific Sessions. The analysis did not track nonfatal heart attacks, repeat procedures or quality of life beyond the initial trial period.
Nootropics Depot
Nootropics Depot Publishes Retail Market Research Measuring 68 Products Across 8 Ingredients
Nootropics Depot published lab measurements of 68 retail products across 8 ingredients, 15 of them its own, which it says were tested by the same method using products bought from retail sources. The company reports that 6 of 10 competing lion's mane products measured no erinacine A, while noting one competing Cistanche product measured higher echinacoside than its own.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Stream Bulletin reporting.